



Al Hammadi's latest Q3-22 results came to positively surprise the market consensus by recording a net profit for the quarter at SAR 57.1mn (almost 17.6% above market expectations of SAR 48.6mn, yet in line with our anticipated SAR 54.4mn at a deviation of 5%). Al Hammadi posted a declined net income by 7.8% on the Q/Q scale, yet its bottom line grew from the same quarter in FY21 (from a modest SAR 3.6mn, due to the one off losses recorded in Q3-21 from the disposal of Al Olaya's Hospital). Adjusting for the one off loss in Q3-21, Al Hammadi's Y/Y bottom line growth stood at a 41.6% increase. While the seasonal nature of Q3 on the sector pressured Al Hammadi's medical and pharmaceutical operations, the firm's bottom line on the Y/Y scale was supported by higher patient volumes as sales have grown by almost 12.3% Y/Y. We maintain our "Neutral" recommendation on the firm while revising our TP higher to SAR 44.5/share.

- Al Hammadi posted a net profit of SAR 57.1mn (up by over 1,000% Y/Y, or 41.6% when adjusting for the one off loss in Q3-21, and down 7.8% Q/Q). Results stood above the market estimated SAR 44.8mn by 17.6%, yet in line with our expected of SAR 54.4mn at a 5.0% deviation). Higher revenues from increased patient volumes supported the Y/Y growth, while the seasonal effect on Q3 along with the holidays during then took a toll on the firm's Q/Q bottom line change. The release of a government grant totalling to over SAR 15mn also propelled the quarter's bottom line higher. The slight deviation from our estimates were driven by the worse than expected GP margins reported.
- The revenues seen by Al Hammadi in Q3-22 reached SAR 246.9mn at a 12.3% Y/Y increase (down 12.4% Q/Q from SAR 281.9mn as a result of the holiday season's effect on the sector). This came in in-line with our expectations of SAR 260.3mn with a deviation of 5.1%. Driving the increase in revenues is the higher inpatient and outpatient volumes across both operating hospitals.
- Gross profits stood at SAR 83.5mn (down 5.3% Y/Y, and 23.5% Q/Q), deviating from our expectations of SAR 100.6mn by 17.0%. GP margins significantly missed our expectations of 38.7% and contracted by 630bps Y/Y and 450bps Q/Q to reach 33.8%. The contracted GP margins for Q3 represent an almost 30th percentile result for the company's historical GP margins.
- Operating income stood, when deducting the government grant released, reached SAR 52.3mn (almost flat on a Y/Y scale, yet down 29.2% Q/Q). Operating income met our estimates of exactly SAR 66.20mn when recording the grant, yet effectively is deviated from the SAR 52.3mn in operating income by 21.0%. We have overestimated the OPEX for the firm at 13.2% of revenues, expecting it to edge a little higher than the previous quarter yet less than Q3-21. Al Hammadi's OPEX however came at 12.6% of revenues, down 370bps Y/Y and up 10bps Q/Q.

AJC view and valuation: Al Hammadi posted a growing top line figure on a Y/Y arising from improved utilization rates at the firm's Al Suwaidi and Al Nuzha hospitals. With more headroom in utilization rates, we are monitoring the growth in volumes for Al Hammadi for the coming periods. Among the growing top line, we are also monitoring for any changes in the firm's receivables to revenues. Al Hammadi's three-year average of receivables as a percentage of revenues sits above the sector figure of 45.8% of revenues. Yet we do however anticipate an improvement in the receivables recorded per revenues in the coming three years, as the firm migrated its collection process onto the Nafees program which management indicates is paying in time. We reiterate our view that cost optimization, and reduction in provisions are expected to drive margins in the medium term. The firm's limited geographic diversification, a delay in construction of the new Al Olaya facility, and competition from sector peers such as Dallah, HMG, Mouwasat and MEH pose major risks. We do favor the firm's commitment to steadily increasing the dividend payout in the coming periods as well, as we see it as a positive signal from the firm for the coming years. We remain "Neutral" on the Al Hammadi while raising our TP to SAR 44.5/share, while we maintain monitoring our key gauges for the firm.

Results Summary

| SARmn | Q3-21 | Q2-22 | Q3-22 | Change Y/Y | Change Q/Q | Deviation from AJC Estimates |
|------------------|-------|-------|-------|------------|------------|------------------------------|
| Revenue | 219.9 | 281.9 | 246.9 | 12.3% | -12.4% | -5.1% |
| Gross Profit | 88.2 | 109.1 | 83.5 | -5.3% | -23.5% | -17.0% |
| Gross Margin | 40.1% | 38.3% | 33.8% | - | - | - |
| Operating Income | 52.2 | 73.9 | 52.3 | 0.1% | -29.2% | -21.0% |
| Net Profit | 3.6 | 62.0 | 57.1 | 1495.3% | -7.8% | 5.0% |
| EPS | 0.02 | 0.39 | 0.41 | - | - | - |

Source: Company Reports, Aljazeera Capital

| Recommendation | Neutral |
|----------------------|---------|
| Target Price (SAR) | 44.5 |
| Upside / (Downside)* | 5.5% |

Source: Tadawul *prices as of 21th of Nov 2022

Key Financials

| SARmn (unless specified) | FY20 | FY21 | FY22E | FY23E |
|--------------------------|--------|--------|---------|---------|
| Revenue | 764.1 | 951.9 | 1,062.1 | 1,121.1 |
| Growth % | -21.6% | 24.6% | 11.6% | 5.6% |
| Net Income | 130.8 | 90.1 | 247.7 | 249.1 |
| Growth % | 40.7% | -31.1% | 174.9% | 0.6% |
| EPS | 0.82 | 0.56 | 1.55 | 1.56 |

Source: Company reports, Aljazeera Capital

Key Ratios

| | FY20 | FY21 | FY22E | FY23E |
|---------------|-------|-------|-------|-------|
| Gross Margin | 33.1% | 38.2% | 36.7% | 36.6% |
| Net Margin | 17.1% | 9.5% | 23.3% | 22.2% |
| P/E (x) | 71.9 | 48.9 | 27.3 | 27.1 |
| P/B (x) | 2.0 | 2.2 | 3.7 | 3.5 |
| EV/EBITDA (x) | 21.9 | 27.3 | 17.8 | 16.3 |


Source: Company reports, Aljazeera Capital

Key Market Data

| | |
|-------------------------|------------|
| Market Cap (bn) | 6.65 |
| YTD % | 38.9% |
| 52 Week (High)/(Low) | 50.0/26.82 |
| Shares Outstanding (mn) | 160.0 |

Source: Company reports, Aljazeera Capital

Stock Performance



Source: Company reports, Aljazeera Capital

Equity Analyst

Ibrahim Elaiwat

+966 11 225 6115

i.elaiwat@aljazaracapital.com.sa



RESEARCH DIVISION

Head of Sell-Side Research
Jassim Al-Jubran
+966 11 2256248
j.aljabran@aljaziracapital.com.sa

RESEARCH DIVISION

AlJazira Capital, the investment arm of Bank AlJazira, is a Shariaa Compliant Saudi Closed Joint Stock company and operating under the regulatory supervision of the Capital Market Authority. AlJazira Capital is licensed to conduct securities business in all securities business as authorized by CMA, including dealing, managing, arranging, advisory, and custody. AlJazira Capital is the continuation of a long success story in the Saudi Tadawul market, having occupied the market leadership position for several years. With an objective to maintain its market leadership position, AlJazira Capital is expanding its brokerage capabilities to offer further value-added services, brokerage across MENA and International markets, as well as offering a full suite of securities business.

RATING TERMINOLOGY

1. **Overweight:** This rating implies that the stock is currently trading at a discount to its 12 months price target. Stocks rated "Overweight" will typically provide an upside potential of over 10% from the current price levels over next twelve months.
2. **Underweight:** This rating implies that the stock is currently trading at a premium to its 12 months price target. Stocks rated "Underweight" would typically decline by over 10% from the current price levels over next twelve months.
3. **Neutral:** The rating implies that the stock is trading in the proximate range of its 12 months price target. Stocks rated "Neutral" is expected to stagnate within +/- 10% range from the current price levels over next twelve months.
4. **Suspension of rating or rating on hold (SR/RH):** This basically implies suspension of a rating pending further analysis of a material change in the fundamentals of the company.

Disclaimer

The purpose of producing this report is to present a general view on the company/economic sector/economic subject under research, and not to recommend a buy/sell/hold for any security or any other assets. Based on that, this report does not take into consideration the specific financial position of every investor and/or his/her risk appetite in relation to investing in the security or any other assets, and hence, may not be suitable for all clients depending on their financial position and their ability and willingness to undertake risks. It is advised that every potential investor seek professional advice from several sources concerning investment decision and should study the impact of such decisions on his/her financial/legal/tax position and other concerns before getting into such investments or liquidate them partially or fully. The market of stocks, bonds, macroeconomic or microeconomic variables are of a volatile nature and could witness sudden changes without any prior warning, therefore, the investor in securities or other assets might face some unexpected risks and fluctuations. All the information, views and expectations and fair values or target prices contained in this report have been compiled or arrived at by Al-Jazira Capital from sources believed to be reliable, but Al-Jazira Capital has not independently verified the contents obtained from these sources and such information may be condensed or incomplete. Accordingly, no representation or warranty, express or implied, is made as to, and no reliance should be placed on the fairness, accuracy, completeness or correctness of the information and opinions contained in this report. Al-Jazira Capital shall not be liable for any loss as that may arise from the use of this report or its contents or otherwise arising in connection therewith. The past performance of any investment is not an indicator of future performance. Any financial projections, fair value estimates or price targets and statements regarding future prospects contained in this document may not be realized. The value of the security or any other assets or the return from them might increase or decrease. Any change in currency rates may have a positive or negative impact on the value/return on the stock or securities mentioned in the report. The investor might get an amount less than the amount invested in some cases. Some stocks or securities maybe, by nature, of low volume/trades or may become like that unexpectedly in special circumstances and this might increase the risk on the investor. Some fees might be levied on some investments in securities. This report has been written by professional employees in Al-Jazira Capital, and they undertake that neither them, nor their wives or children hold positions directly in any listed shares or securities contained in this report during the time of publication of this report, however, The authors and/or their wives/children of this document may own securities in funds open to the public that invest in the securities mentioned in this document as part of a diversified portfolio over which they have no discretion. This report has been produced independently and separately by the Research Division at Al-Jazira Capital and no party (in-house or outside) who might have interest whether direct or indirect have seen the contents of this report before its publishing, except for those whom corporate positions allow them to do so, and/or third-party persons/institutions who signed a non-disclosure agreement with Al-Jazira Capital. Funds managed by Al-Jazira Capital and its subsidiaries for third parties may own the securities that are the subject of this document. Al-Jazira Capital or its subsidiaries may own securities in one or more of the aforementioned companies, and/or indirectly through funds managed by third parties. The Investment Banking division of Al-Jazira Capital maybe in the process of soliciting or executing fee earning mandates for companies that is either the subject of this document or is mentioned in this document. One or more of Al-Jazira Capital board members or executive managers could be also a board member or member of the executive management at the company or companies mentioned in this report, or their associated companies. No part of this report may be reproduced whether inside or outside the Kingdom of Saudi Arabia without the written permission of Al-Jazira Capital. Persons who receive this report should make themselves aware, of and adhere to, any such restrictions. By accepting this report, the recipient agrees to be bound by the foregoing limitations.

Asset Management | Brokerage | Investment Banking | Custody | Advisory

Head Office: King Fahad Road, P.O. Box: 20438, Riyadh 11455, Saudi Arabia. Tel: 011 2256000 - Fax: 011 2256068